<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680417</url>
  </required_header>
  <id_info>
    <org_study_id>PMS-MR-0417</org_study_id>
    <nct_id>NCT03680417</nct_id>
  </id_info>
  <brief_title>Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children</brief_title>
  <official_title>Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to assess safety and immunogenicity of measles-rubella (MR) routine immunization in
      Indonesian Children and Infants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  to asses serious immediate systemic events,

        -  to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and
           children,

        -  to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR
           vaccine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 26, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Safety Group: open labeled, prospective intervention study, only assess the safety outcome Sub Group: open labeled, prospective intervention study, evaluate safety and protectivity outcome</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>laboratory analyst are masked for the evaluation of antibody against measles and rubella. The immunogenicity is measured before and after vaccination.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Immediate systemic events</measure>
    <time_frame>30 minutes</time_frame>
    <description>Number of subjects with at least one serious immediate systemic events within 30 minutes after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of immediate systemic events</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percentage of subjects with at least one serious immediate systemic events within 30 minutes after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local reaction</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of subjects with at least one local reaction occurring within 72 h after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic reaction</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of subjects with at least one systemic event occurring within 72 h after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Local reaction</measure>
    <time_frame>11 days</time_frame>
    <description>Number of subjects with at least one local reaction occurring between day 4-14 after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed systemic event</measure>
    <time_frame>11 days</time_frame>
    <description>Number of subjects with at least one systemic event occurring between day 4-14 after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Local reaction</measure>
    <time_frame>14 days</time_frame>
    <description>-Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Safety (Systemic event)</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects with at least one systemic event occurring between day 15 to 28 following vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (serious adverse event)</measure>
    <time_frame>28 days</time_frame>
    <description>- Number of serious adverse event occuring from inclusion until 28 days after immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Measles (subject with anti measles titer ≥ 8 (1/dil))</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of subjects with anti measles titer ≥ 8 (1/dil), 28 days after one dose of MR vaccine in Infants &amp; Children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Measles (Geometric Mean Titer)</measure>
    <time_frame>28 days</time_frame>
    <description>- Geometric Mean Titer of measles antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Measles (increasing measles antibody titer ≥ 4 times)</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of infants with increasing measles antibody titer ≥ 4 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Measles (seroconversion from seronegative to seropositive)</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of infants with transition of seronegative to seropositive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Rubella (Subjects with anti rubella titer ≥11 IU/ml)</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of subjects with anti rubella titer ≥11 IU/ml, 28 days after one dose of MR vaccine in Infants &amp; Children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Rubella (Geometric Mean Titer)</measure>
    <time_frame>28 days</time_frame>
    <description>- Geometric Mean Titer of Rubella antibody.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Rubella (increasing rubella antibody titer ≥ 4 times)</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of infants with increasing rubella antibody titer ≥ 4 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity for Rubella (seroconversion from seronegative to seropositive)</measure>
    <time_frame>28 days</time_frame>
    <description>- Percentage of infants with transition of seronegative to seropositive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">590</enrollment>
  <condition>Safety Issues</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>Safety Study (Measles-Rubella vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub Study (Measles-Rubella vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles-Rubella (MR) Vaccine</intervention_name>
    <description>Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.</description>
    <arm_group_label>Safety Study (Measles-Rubella vaccine)</arm_group_label>
    <arm_group_label>Sub Study (Measles-Rubella vaccine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants (9-12 months) or children (18-47 months)

          -  Will receive MR routine immunization.

          -  Parents have been informed properly regarding the study and signed the informed
             consent form.

          -  Parents will commit themselves to comply with the instructions of the investigator and
             the schedule of the trial.

        Exclusion Criteria:

          -  MR vaccine given simultaneously with other vaccination, except Pentabio (DTP/HB/Hib)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominicus Husada, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Child Health Dept. Dr. Soetomo Hospital/School of Medicine, Airlangga Univ.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ.</name>
      <address>
        <city>Surabaya</city>
        <state>East Java</state>
        <zip>60131</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Measles-Rubella</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Reactogenicity</keyword>
  <keyword>Protectivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

